购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

PF04929113

产品编号 T6341Cas号 908115-27-5
别名 SNX-5422, PF-04929113, PF 04929113

PF04929113 (SNX-5422) 是一种合成的新型小分子 Hsp90 抑制剂。作为一种具有强大疗效和耐受性的口服制剂,它被定位为一种突破性疗法,在广泛的癌症中具有广泛的适用性。

PF04929113

PF04929113

纯度: 99.06%
产品编号 T6341 别名 SNX-5422, PF-04929113, PF 04929113Cas号 908115-27-5

PF04929113 (SNX-5422) 是一种合成的新型小分子 Hsp90 抑制剂。作为一种具有强大疗效和耐受性的口服制剂,它被定位为一种突破性疗法,在广泛的癌症中具有广泛的适用性。

规格价格库存数量
1 mg¥ 315现货
2 mg¥ 453现货
5 mg¥ 747现货
10 mg¥ 997现货
25 mg¥ 2,160现货
50 mg¥ 3,230现货
100 mg¥ 4,990现货
1 mL x 10 mM (in DMSO)¥ 855现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"PF04929113"的相关化合物库

选择批次:
纯度:99.06%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
PF04929113 (SNX-5422) is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, PF04929113 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
靶点活性
HER2:37 nM, HSP90:41 nM
体外活性
免疫组织化学分析表明,在用PF-04929113处理后,SP70表达增加,并降低Ki67,Akt和AR表达.PF-04929113在体内抑制人类MM细胞生长,并且免疫组织化学分析显示PF-04929113显著抑制处理的小鼠中的p-ERK和p-Akt.同时,PF-04929113处理显著降低CD31+细胞和MVD百分比,与体内血管生成的抑制作用一致.PF-04929113对肿瘤发展的抑制可能由增殖减少(Ki67和Akt表达降低)或凋亡率增加(增加的ApopTag染色)共同引起.
体内活性
PF-04929113对Her-2稳定性表现出有效的作用并导致预期的Hsp70上调。PF-04929113显示针对广泛癌症细胞类型的有效抗增殖活性,例如,MCF-7(IC50 = 16 nM),SW620(IC50 = 19 nM),K562(IC50 = 23 nM),SK-MEL-5(IC50 = 25 nM)和A375(IC50 = 51 nM)。
激酶实验
The Hsp90 loaded media is challenged with PF-04929113 at a given concentration, ranging from 0.8 to 500 μM, and the amount of Hsp90 liberated at each concentration is determined by Bradford protein assay. The resulting IC50 values are corrected for the ATP ligand concentration and presented as apparent Kd values.
细胞实验
Cell lines: MCF-7,SW620,K562,SK-MEL-5 and A375 cancer cell lines. Concentrations: 0-300 nM. Method: Proliferation rates are measured by seeding cells into 96-well plates,followed by compound addition 24 h later.After addition of PF-04929113,cells are allowed to grow for either an additional 72 or 144 h depending on the rate of growth.At harvest,media is removed and DNA content for individual wells is determined using CyQuant DNA dye.Levels of Hsp90 client proteins and phosphor-regulated proteins in A375 are measured by high content analysis (HCA) using an ArrayScan 4.5 instrument after 24 hours of treatment with PF-04929113,followed by methanol fixation.After fixation in 4% PBS-buffered formalin and permeablization with 0.1% TX-100,cells are probed with anti-Her2,antiphospho-S6 (pS6),antipERK,and anti-Hsp70 primary antibodies,followed by TRITC or FITC conjugated secondary antibodies.Nuclei are also stained with Hoechst DNA binding dye.For each well,250-500 individual nuclei are identified along with the average staining intensity for the client and phospho-proteins for each cell.Average client staining intensities are then calculated for each well.
动物实验
Animal Models: 5 ×106 MM.1S cells are inoculated subcutaneously in the Fox Chase SCID mice (6-7 weeks old). Formulation: PF-04929113 is dissolved in 1% carboxy methylcellulose/0.5% Tween 80 at 10 mg/mL and stored at 4 °C. Dosages: 20 or 40 mg/kg. Administration: orally 3 times per week,3 weeks in total.
别名SNX-5422, PF-04929113, PF 04929113
化学信息
分子量521.53
分子式C25H30F3N5O4
CAS No.908115-27-5
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 3 mg/mL (5.8 mM)
DMSO: 96 mg/mL (184.1 mM)
溶液配制表
Ethanol/DMSO
1mg5mg10mg50mg
1 mM1.9174 mL9.5872 mL19.1744 mL95.8718 mL
5 mM0.3835 mL1.9174 mL3.8349 mL19.1744 mL
DMSO
1mg5mg10mg50mg
10 mM0.1917 mL0.9587 mL1.9174 mL9.5872 mL
20 mM0.0959 mL0.4794 mL0.9587 mL4.7936 mL
50 mM0.0383 mL0.1917 mL0.3835 mL1.9174 mL
100 mM0.0192 mL0.0959 mL0.1917 mL0.9587 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy PF04929113 | purchase PF04929113 | PF04929113 cost | order PF04929113 | PF04929113 chemical structure | PF04929113 in vivo | PF04929113 in vitro | PF04929113 formula | PF04929113 molecular weight